A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
MRI biomarker
Parkinson's disease
clinical practice
progressive supranuclear palsy
third ventricle width
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
02
09
2020
received:
08
07
2020
accepted:
12
10
2020
pubmed:
6
11
2020
medline:
28
4
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
Enlargement of the third ventricle has been reported in atypical parkinsonism. We investigated whether the measurement of third ventricle width could distinguish Parkinson's disease (PD) from progressive supranuclear palsy (PSP). We assessed a new MR T1-weighted measurement (third ventricle width/internal skull diameter) in a training cohort of 268 participants (98 PD, 73 PSP, 98 controls from our center) and in a testing cohort of 291 participants (82 de novo PD patients and 133 controls from the Parkinson's Progression Markers Initiative, 76 early-stage PSP from an international research group). PD diagnosis was confirmed after a 4-year follow-up. Diagnostic performance of the third ventricle/internal skull diameter was assessed using receiver operating characteristic curve with bootstrapping; the area under the curve of the training cohort was compared with the area under the curve of the testing cohort using the De Long test. In both cohorts, third ventricle/internal skull diameter values did not differ between PD and controls but were significantly lower in PD than in PSP patients (P < 0.0001). In PD, third ventricle/internal skull diameter values did not change significantly between baseline and follow-up evaluation. Receiver operating characteristic analysis accurately differentiated PD from PSP in the training cohort (area under the curve, 0.94; 95% CI, 91.1-97.6; cutoff, 5.72) and in the testing cohort (area under the curve, 0.91; 95% CI, 87.0-97.0; cutoff,: 5.88), validating the generalizability of the results. Our study provides a new reliable and validated MRI measurement for the early differentiation of PD and PSP. The simplicity and generalizability of this biomarker make it suitable for routine clinical practice and for selection of patients in clinical trials worldwide. © 2020 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Enlargement of the third ventricle has been reported in atypical parkinsonism. We investigated whether the measurement of third ventricle width could distinguish Parkinson's disease (PD) from progressive supranuclear palsy (PSP).
METHODS
We assessed a new MR T1-weighted measurement (third ventricle width/internal skull diameter) in a training cohort of 268 participants (98 PD, 73 PSP, 98 controls from our center) and in a testing cohort of 291 participants (82 de novo PD patients and 133 controls from the Parkinson's Progression Markers Initiative, 76 early-stage PSP from an international research group). PD diagnosis was confirmed after a 4-year follow-up. Diagnostic performance of the third ventricle/internal skull diameter was assessed using receiver operating characteristic curve with bootstrapping; the area under the curve of the training cohort was compared with the area under the curve of the testing cohort using the De Long test.
RESULTS
In both cohorts, third ventricle/internal skull diameter values did not differ between PD and controls but were significantly lower in PD than in PSP patients (P < 0.0001). In PD, third ventricle/internal skull diameter values did not change significantly between baseline and follow-up evaluation. Receiver operating characteristic analysis accurately differentiated PD from PSP in the training cohort (area under the curve, 0.94; 95% CI, 91.1-97.6; cutoff, 5.72) and in the testing cohort (area under the curve, 0.91; 95% CI, 87.0-97.0; cutoff,: 5.88), validating the generalizability of the results.
CONCLUSION
Our study provides a new reliable and validated MRI measurement for the early differentiation of PD and PSP. The simplicity and generalizability of this biomarker make it suitable for routine clinical practice and for selection of patients in clinical trials worldwide. © 2020 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 33151015
doi: 10.1002/mds.28364
pmc: PMC8330364
mid: NIHMS1726629
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-689Subventions
Organisme : NINDS NIH HHS
ID : R01 NS052318
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS102038
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
Mov Disord. 2019 Apr;34(4):487-495
pubmed: 30759325
Mov Disord. 2017 Jun;32(6):842-852
pubmed: 28436538
Mov Disord. 2020 Jun;35(6):976-983
pubmed: 32092195
JAMA Neurol. 2014 Jan;71(1):62-7
pubmed: 24190026
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Parkinsonism Relat Disord. 2016 Jul;28:107-11
pubmed: 27160570
Neurology. 2016 Feb 9;86(6):566-76
pubmed: 26764028
Radiology. 2017 Oct;285(1):197-205
pubmed: 28498794
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759
Mov Disord. 2020 Aug;35(8):1406-1415
pubmed: 32396693
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurology. 2013 May 14;80(20):1856-61
pubmed: 23616165
Parkinsonism Relat Disord. 2018 Sep;54:3-8
pubmed: 30068492
Mov Disord. 2017 Jul;32(7):955-971
pubmed: 28500751
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Arch Neurol. 2007 Nov;64(11):1635-40
pubmed: 17998447
Parkinsonism Relat Disord. 2019 Nov;68:40-45
pubmed: 31621617
Alzheimers Dement (Amst). 2019 Apr 02;11:301-309
pubmed: 30984816
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Parkinsonism Relat Disord. 2018 Jan;46:47-55
pubmed: 29126761
Parkinsonism Relat Disord. 2011 Mar;17(3):172-6
pubmed: 21236720
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
pubmed: 30564614